Delivering Belantamab Mafodotin in Relapsed or Refractory Multiple Myeloma Discussing Patient Selection, Ocular Monitoring, and Multidisciplinary Workflow

Experts explain who benefits from belantamab in relapsed myeloma and how REMS eye exams and dose tweaks keep treatment on track.

DREAMM-7 reveals belantamab combo extends myeloma PFS, with reversible eye effects, REMS monitoring, and fewer severe infections.

Practical guidance for starting belantamab: confirm eligibility, coordinate ophthalmology exams, manage reversible eye toxicity with dose holds, and educate patients for confident dosing.

Experts explain how myeloma regimens manage eye toxicity with baseline exams, dose holds, reductions, and longer belantamab dosing intervals to improve safety.

One panelist addresses neuropathy in a patient who has received bortezomib, describing a symptom-driven approach.

The moderator asks whether any of the patient’s baseline comorbidities from the clinical scenario in the previous episode are a concern.

The moderator and the panelists then discuss how to prepare the patient for the first cycles.

One panelist reassures a responding patient whose dose is held that benefit does not depend on every-3-week dosing and that the eye has the ability to heal on its own, noting that patients at longer intervals in the study maintained benefit, some doing better by staying on treatment longer.

The program concludes with panelists discussing what would improve deliverability of the regimen in the community.